CytomX Therapeutics Inc (CTMX)
NASDAQ:CTMX
Want to see CTMX full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.08Last Year’s EPS
0Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized substantial clinical progress and clear near-term development and regulatory plans for Varseta-M (robust ORR 20%–32% and ~7 months PFS, completed optimization enrollment, combination and expansion strategies), backed by a materially strengthened balance sheet (cash up ~152.9%) and runway into H2 2028. Key risks remain operational and clinical: a large year-over-year revenue decline driven by completed collaborations, modest increases in operating costs, and the need to confirm that Grade 3 diarrhea can be reliably managed in the full optimization cohort and over longer follow-up. Overall, the positive clinical momentum and strong cash position outweigh the near-term financial and clinical uncertainties.Company Guidance
Strong Varseta-M Clinical Activity
Phase I updated efficacy in late-line metastatic colorectal cancer: confirmed overall response rate (ORR) between 20% and 32% and median progression-free survival (PFS) of approximately 7 months — materially higher than current therapies which show single-digit ORRs and only a few months of PFS.
Completed Dose Optimization Enrollment; Path to Registrational Study
Dose optimization cohorts now fully enrolled with 40 patients at 8.6 and 10 mg/kg, taking total Phase I enrollment to 113 patients. Company on track to prioritize one dose and advance into a registrational (pivotal) late-line CRC study targeted for the first half of 2027.
Safety Management Progress for Varseta-M
Updated adverse event management strategies (upfront loperamide and budesonide) showed preliminary improvement: initial look from the first 20 optimization patients reported Grade 3 diarrhea at ~10%. Company target is to manage Grade 3 diarrhea into a 10%–20% range.
Combination and Expansion Strategy to Enable Earlier Lines
Initiated Varseta-M + bevacizumab combination (q2w and q4w schedules) with initial data expected by H1 2027; plan to start a Phase I/II chemotherapy (triplet including bevacizumab) combination study in H2 2026; Phase I expansion cohorts in additional EpCAM-expressing indications planned in H2 2026 to support pan-tumor strategy.
Progress on CX-801 (Masked IFN-α2b)
CX-801 advanced to the fourth dose level in monotherapy (exceeding approved clinical dose of unmasked interferon alpha-2b) and has been well tolerated to date. Combination dose escalation with KEYTRUDA is enrolling (third dose level). Initial clinical data expected by year-end.
Strengthened Balance Sheet and Runway
Closed financing in March and ended Q1 2026 with $346.7 million in cash, cash equivalents and investments versus $137.1 million at 12/31/2025 — a cash increase of ~152.9% — with projected runway to at least the second half of 2028, enabling planned advancement of Varseta-M into a registrational study.
Focused Capital Allocation and Execution Plan
Company communicated disciplined capital allocation with near- to medium-term prioritization of Varseta-M programs (monotherapy registrational path, bev and chemo combinations, and non-CRC expansions) and expectations to deliver multiple clinical readouts through 2026–2027.
Planned Data and Regulatory Timeline
Company expects an overall Phase I data update including safety and efficacy from the monotherapy dose optimization in the second half of 2026, and multiple FDA interactions in 2026 to inform dose selection and registrational study design.
CTMX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CTMX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $4.00 | $3.98 | -0.50% |
Mar 16, 2026 | $4.68 | $6.75 | +44.23% |
Nov 06, 2025 | $4.19 | $3.62 | -13.60% |
Aug 07, 2025 | $2.10 | $2.35 | +11.90% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does CytomX Therapeutics Inc (CTMX) report earnings?
CytomX Therapeutics Inc (CTMX) is schdueled to report earning on Aug 06, 2026, After Close (Confirmed).
What is CytomX Therapeutics Inc (CTMX) earnings time?
CytomX Therapeutics Inc (CTMX) earnings time is at Aug 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CTMX EPS forecast?
CTMX EPS forecast for the fiscal quarter 2026 (Q2) is -0.08.